CAPR
Capricor Therapeutics, Inc.
There isn't enough reported data to score CAPR yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CAPR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
CAPR's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CAPR PE Valuation
CAPR has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CAPR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CAPR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CAPR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.64 | -$0.89 |
| Q2 2026 | -$2.45 | -$0.86 |
| Q1 2026 | -$2.32 | -$0.95 |
| Q4 2025 | -$2.26 | -$1.11 |
| Q3 2025 | -$1.75 | -$0.68 |
| Q2 2025 | -$1.59 | -$0.65 |
| Q1 2025 | -$1.37 | -$0.49 |
| Q4 2024 | -$1.15 | -$0.27 |
CAPR lost $2.64 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CAPR on earnings quality, reporting a profit while its opponent remains loss making.
CAPR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $11.1M | -7.9% |
| Q3 2024 | $2.3M | -63% |
| Q2 2024 | $4M | +1.4% |
| Q1 2024 | $4.9M | +64% |
| Q4 2023 | $12.1M | +1159% |
| Q3 2023 | $6.2M | +289% |
| Q2 2021 | $204.1K | +309% |
| Q1 2021 | $40.8K | -78% |
LLY has the stronger quarterly revenue trend. Revenue is down 7.9% for CAPR versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -69% | -59 points |
| Q3 2024 | -575% | -464 points |
| Q2 2024 | -292% | -94 points |
| Q1 2024 | -209% | +65 points |
| Q4 2023 | -11% | +830 points |
| Q3 2023 | -111% | +296 points |
| Q2 2023 | -198% | N/A |
| Q1 2023 | -274% | N/A |
CAPR's operating margin was −69% last quarter, down 59 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
CAPR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.5M | -$17.8M |
| Q2 2026 | -$35.5M | -$15.1M |
| Q1 2026 | -$34.4M | -$27M |
| Q4 2025 | -$25.2M | -$9.9M |
| Q3 2025 | -$19.7M | -$8.1M |
| Q2 2025 | -$20.4M | -$8.1M |
| Q1 2025 | -$7.3M | -$5.5M |
| Q4 2024 | -$15.3M | -$3.1M |
CAPR has burned cash in almost every quarter: −$133M over the past year, against −$63M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CAPR on cash generation, producing positive trailing cash flow while its opponent burns cash.
CAPR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +202K shares |
| 1 year | +27% | +12.4M shares |
| 3 years | +129% | +32.8M shares |
| 5 years | +154% | +35.3M shares |
| Available history | +745% | +51.2M shares |
CAPR has 58M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CAPR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CAPR Net Leverage
CAPR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CAPR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 67.4 | Neutral |
CAPR's weekly RSI is 44 (neutral) and its Stochastic is 67 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CAPR PE vs Healthcare Sector
CAPR has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CAPR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.92 | 29% above |
| 20 week MA | $10.2 | 0.1% above |
| 50 week MA | $20.9 | 51% below |
| 100 week MA | $15.5 | 34% below |
| 200 week MA | $10.8 | 5.4% below |
CAPR has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 5.4% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CAPR on trend strength, trading above more of its moving averages.
CAPR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.16 | $3.90 | +236% |
| 2021 | $3.90 | $3.39 | -13% |
| 2022 | $3.39 | $3.52 | +3.8% |
| 2023 | $3.52 | $4.89 | +39% |
| 2024 | $4.89 | $14.1 | +188% |
| 2025 | $14.1 | $29.7 | +111% |
| 2026 YTD | $29.7 | $10.2 | -66% |
CAPR is down 66% so far in 2026, after finishing higher in five of the previous six years.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CAPR on returns for 2026, with the stronger performance.